A criterion-based, progressive mechanotherapy framework for acute and subacute musculoskeletal pain recovery — grounded in mechanotransduction science, validated across four international research sites, and published in the Journal of Movement Mechanics & Biomechanics Science.
The management of acute and subacute musculoskeletal pain has historically relied on passive strategies such as rest and cryotherapy. Contemporary evidence underscores the detrimental effects of prolonged immobilization on mechanotransductive signaling and neuromuscular reactivation. The MOVE Protocol (Mobilize, Optimize, Validate, Energize) was developed to operationalize modern rehabilitation paradigms emphasizing controlled, progressive engagement as a healing catalyst.
To evaluate the clinical effectiveness, feasibility, and safety of the M.O.V.E. Protocol as a criterion-based, four-phase mechanotherapy framework for adults with acute and subacute (<12 weeks) musculoskeletal conditions across multiple international sites.
Prospective, international, multi-site, open-label, single-arm interventional case-series. 40 participants aged 18–65 with musculoskeletal conditions ≤12 weeks duration (baseline NRS ≥4) were enrolled across four sites: MMSx Authority (USA), BodyGNTX Institute (USA), GFFI India, and IIKBS India. The 8-week intervention was structured across four progressive domains: Mobilize, Optimize, Validate, Energize. Primary outcome: pain (NRS). Secondary outcomes: functional index (LEFS/UEFI), balance (SLS), strength (STS), GROC, and time to return to ADL.
Statistically and clinically significant reduction in pain (Δ -5.1 NRS, p<0.001), substantial functional improvement (Δ +27.4 LEFS/UEFI), improved balance (SLS: Δ +13.4 sec), and strength gains (STS: Δ +6.3 reps). Median return to ADL: 14 days (IQR 10–20). Adherence: 82%. Serious adverse events: 0. Minor AEs: 2 (resolved via built-in deload controls). Outcomes were consistent across all four international sites.
The M.O.V.E. Protocol demonstrated superior rehabilitation outcomes across all clinical and functional parameters. The magnitude of improvement exceeded established MCIDs, confirming both statistical significance and real-world clinical relevance. This trial supports the MOVE framework as a viable, evidence-based alternative to conventional passive approaches, aligning rehabilitation with contemporary mechanobiological principles and demonstrating generalizability across diverse international clinical environments.
Central Proposition: Traditional rest and cryotherapy may be suboptimal — and in many cases counterproductive — for acute and subacute musculoskeletal recovery. Early, controlled mechanical loading guided by mechanotransduction principles accelerates tissue repair, maintains neuromuscular integrity, and produces superior clinical outcomes.
Musculoskeletal conditions represent a leading cause of disability globally, generating enormous clinical and economic burden. For decades, standard-of-care recommendations for acute MSK injuries centred on passive strategies: rest, ice, compression, elevation (RICE), and variations thereof. While these approaches may reduce early inflammatory symptoms, contemporary mechanobiology has fundamentally challenged their therapeutic sufficiency.
Prolonged immobilization produces demonstrably detrimental effects: muscle atrophy begins within 24–48 hours, articular cartilage experiences disorganized loading stress, collagen fibers form in suboptimal orientations, and neural drive to the affected region diminishes — collectively producing a recovery environment that is mechanically and neurologically worse than controlled early loading. The emergence of the PEACE & LOVE paradigm (Dubois & Esculier, 2020) and mechanotherapy research (Khan & Scott, 2009) established the theoretical and empirical basis for active, progressive rehabilitation as a superior strategy.
The M.O.V.E. Protocol was developed by Dr. Neeraj Mehta and the MMSx Authority Institute to operationalize these principles into a clinically deployable, criterion-based framework. This was not merely a set of exercises — it was a systematic application of biomechanical and physiological principles: mechanotransduction for tissue repair, neural validation for proprioceptive restoration, and metabolic activation for systemic recovery. The international multi-site case-series (NCT07220200) was designed to provide the rigorous empirical evidence that this paradigm shift required.
Each letter in M.O.V.E. represents a biomechanically and physiologically distinct therapeutic domain. The pillars are interdependent — not sequential stages but concurrent threads that are weighted differently across the 8-week protocol timeline.
Initiates gentle active range of motion, joint oscillations, and breath-led mobility to reduce arthrogenic inhibition, maintain neural drive to the affected tissue, and begin stimulating mechanotransductive signaling without exceeding pain thresholds. This phase leverages the body's natural mechanobiology — cells respond to mechanical stimuli by initiating repair cascades — making even low-load, pain-free movement a powerful therapeutic tool.
Introduces carefully dosed mechanical loading in a progressive hierarchy: isometric → isotonic → eccentric. This systematic progression is critical for organizing collagen fiber alignment along lines of mechanical stress (Wolff's Law), building tissue resilience, and enhancing force production capacity. The 48-hour flare rule — reduce load if symptoms worsen beyond 48 hours — ensures tissue tolerance is never exceeded. Progression gates must be met before advancing.
Pain and injury disrupt proprioceptive afferent signaling, causing central nervous system adaptations that persist even after tissue healing completes — producing the movement dysfunction and reinjury risk that characterizes under-rehabilitated MSK conditions. This pillar directly targets CNS reorganization through balance, perturbation, and step-down challenges. High-quality movement without compensation is the primary criterion for progression, not symptom absence alone.
Recovery from musculoskeletal injury is not a local tissue event — it is a systemic metabolic and circulatory process. Zone 2–3 cardiovascular activity (nasal breathing enforced as a load governor) supports mitochondrial efficiency, enhances perfusion to repairing tissue, improves vagal tone, and prevents the deconditioning that accelerates during passive rest periods. This pillar runs concurrently across all 8 weeks, with intensity scaled to tissue state and NRS.
The M.O.V.E. Protocol was evaluated in a prospective, international, multi-site, open-label, single-arm interventional case-series — registered on ClinicalTrials.gov as NCT07220200 prior to any data collection, in compliance with GCP ICH E6(R2) and the Declaration of Helsinki. The study commenced June 2024 and serves as a rigorous feasibility and pilot investigation that powered the evidence base for future RCT design.
The MOVE Protocol was validated across a geographically and clinically diverse four-site consortium in the United States and India — ensuring generalizability across different clinical environments, patient populations, and healthcare systems.
IIKBS Specialized Mandate: Beyond standard clinical data collection, IIKBS was uniquely responsible for applied biomechanics testing and cross-site data validation — utilizing 3D motion capture, force platform analysis, and kinematic assessment to ensure that reported functional improvements were underpinned by genuine, objectively measurable changes in movement quality and biomechanical efficiency. This validation layer, led by Dr. Ben Carter (biostatistician), ensured scientific integrity of the multi-site dataset.
The MOVE Protocol unfolds across four clinically defined progression phases, each with increasing mechanical demand and specific therapeutic targets. Progression between phases is criterion-based — not time-based — meaning participants advance only when defined safety and performance gates are met.
The opening phase prioritizes comfort within movement and the initiation of mechanotransductive healing cascades. Pain-free active ROM and gentle joint oscillations stimulate fibroblast activity, promote synovial fluid circulation, and maintain the neural connections to the affected region that passive rest would otherwise allow to attenuate. The 48-hour monitoring window begins from day one.
The longest and mechanically richest phase. Loading progresses systematically from isometric through isotonic to eccentric emphasis, with load prescription tied to NRS response and the 48-hour flare rule. The eccentric loading bias in the final weeks of this phase is specifically selected to maximize collagen fiber alignment along mechanical stress vectors — a process that passive rest cannot replicate. Week 4 assessment reviews whether criteria are met to progress to Phase 3.
Injury-driven proprioceptive disruption persists beyond tissue healing and is responsible for the majority of reinjury events. This phase systematically challenges the nervous system with progressive balance, perturbation, and deceleration tasks — rebuilding the sensorimotor loop that governs safe functional movement. High-quality movement without compensation is the criterion for progression, not symptom absence alone. Overlaps significantly with Phase 2 loading.
The Energize pillar is unique in that it runs concurrently throughout all 8 weeks rather than as a sequential phase. Tissue repair is a systemically metabolic process: enhanced perfusion, mitochondrial efficiency, and HRV recovery quality all directly influence healing rate. Zone 2–3 cardiovascular activity with enforced nasal breathing is the vehicle — both stimulating circulatory support and providing a built-in intensity governor that prevents overloading injured tissue through cardiovascular fatigue. Week 8 marks formal return-to-ADL evaluation.
The MOVE Protocol's exceptional safety record (0 serious adverse events across 40 participants) is not incidental — it reflects a deliberately engineered progression control system that governs every load increase and phase transition.
Adverse Event Record: 2 minor adverse events occurred across 40 participants (5%) — both were transient symptom exacerbations resolved within 48 hours via the built-in deload protocol. Zero serious adverse events were recorded. Zero discontinuations occurred due to adverse effects. This safety profile provides strong support for the protocol's tolerability in clinical deployment.
All primary and secondary outcomes demonstrated statistically and clinically meaningful improvement. Effect magnitudes exceeded established MCIDs across every measured domain. Outcomes were consistent across all four international sites, strengthening generalizability.
| Outcome Measure | Baseline (Mean ± SD) | Week 8 (Mean ± SD) | Δ Change | Clinical Significance |
|---|---|---|---|---|
| Pain Intensity (NRS 0–10) | 6.8 ± 1.1 | 1.7 ± 1.3 | -5.1 | MCID exceeded (>2.0) |
| Functional Index (LEFS/UEFI) | 55.1 ± 12.3 | 82.5 ± 10.8 | +27.4 | 3× MCID threshold |
| Balance — Single-Leg Stance (sec) | 19.2 ± 7.5 | 32.6 ± 8.2 | +13.4 | Clinically significant |
| Strength — Sit-to-Stand (30 sec reps) | 13.8 ± 3.1 | 20.1 ± 3.4 | +6.3 | Clinically significant |
| Median Return to ADL (days) | — | 14 (IQR 10–20) | 14 days | Primary milestone met |
| Adherence Rate (%) | — | 82% | — | High engagement |
The M.O.V.E. Protocol demonstrated an outstanding tolerability profile. Two minor adverse events occurred (5% rate) — both were transient symptom exacerbations that resolved completely within 48 hours through the protocol's built-in deload mechanism. No participants discontinued due to adverse effects. The 48-hour flare rule and NRS monitoring architecture functioned as designed, preventing symptom exacerbations from progressing to clinically significant complications.
The safety profile is particularly notable given the protocol's active-loading nature, which might be expected to carry higher risk than passive approaches. These results confirm that criterion-based progression — governed by objective NRS thresholds and time-based flare response rules — is a clinically safe framework for mechanotherapy delivery in diverse MSK populations across multiple international settings.
The MOVE Protocol is designed for practical deployment across a range of clinical environments — from physiotherapy clinics and sports medicine settings to rehabilitation centers and exercise-based health practices.
MMSx Authority is committed to transparent, responsible reporting. The MOVE Protocol pilot study, while producing compelling and consistent results, carries inherent methodological limitations that must be acknowledged and that directly inform the next phase of research.
Primary Limitations: (1) Absence of a control group — without a randomized comparator arm, it is not possible to definitively attribute outcomes to the MOVE Protocol itself versus natural history, time, and regression to the mean. (2) Short follow-up period (8 weeks) — long-term durability of outcomes has not been established. (3) Open-label design — participants and assessors were aware of treatment assignment, introducing potential assessment bias. (4) Diagnostic heterogeneity — the protocol was tested across varied MSK presentations, which strengthens generalizability but reduces homogeneity within the sample. (5) Feasibility sample size (n=40) — the sample was powered for feasibility and pilot objectives, not for definitive effect size estimation with narrow confidence intervals.
These limitations are not weaknesses of the protocol itself but of the study design appropriate to a pilot feasibility investigation. The consistent cross-site results, exceptional safety profile, and clinically meaningful effect sizes across all outcome domains provide a robust basis for the next research phase: a fully powered, randomized controlled trial with a comparator arm and long-term follow-up.
Collaboration Welcome: MMSx Authority invites universities, physiotherapy departments, sports medicine clinics, and rehabilitation research groups to join the next phase of MOVE Protocol validation. Contact us at research@mmsxauthority.org or apply at mmsxauthority.org/partnerships.